| Kathi Theade, MD | |
|
1233 N 30th St, Billings, MT 59101-0127 | |
| (406) 237-4116 | |
| (406) 237-4125 |
| Full Name | Kathi Theade |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 1233 N 30th St, Billings, Montana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922024629 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 8635 (Montana) | Primary |
| Entity Name | Scl Health Montana |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083655997 PECOS PAC ID: 3476457714 Enrollment ID: O20031229000380 |
News Archive
Direct Immunofluorescence Assay testing for H1N1 influenza is unreliable in ICU patients, according to a new study from Stanford University. Multiple methods exist for diagnosing influenza, but data on the utility and accuracy of these tests for H1N1 are still emerging, given the relatively recent onset of the epidemic.
In an article published online this week in Nature Genetics, a University of Colorado Cancer Center team in partnership with universities in China and Denmark reports the first genetic sequencing of urothelial (transitional) carcinoma, the most prevalent type of bladder cancer.
Black women have higher recurrence and mortality rates than non-Hispanic white women for certain types of breast cancer, according to a University of Illinois Chicago researcher's study published recently in JAMA Oncology.
Tecan is working with Miltenyi Biotec, a leading provider of cell biology solutions, to develop a range of automated solutions for cell biology, based on the powerful MACS(R) Magnetic bead technology. This new agreement will allow customers to benefit from the advanced capabilities of Tecan's Freedom EVO(R) liquid handling platforms when performing a wide range of separation, cultivation and analysis processes for cells and biomolecules.
Scientists from Virginia Commonwealth University Massey Cancer Center have provided evidence from preclinical experiments that a gene known as melanoma differentiation associated gene-9/syntenin (mda-9/syntenin) could be used as a therapeutic target to kill bladder cancer cells, help prevent metastasis and even be used to non-invasively diagnose the disease and monitor its progression.
› Verified 6 days ago
| Entity Name | Scl Health Medical Group - Billings Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508289703 PECOS PAC ID: 9638491574 Enrollment ID: O20141204001495 |
News Archive
Direct Immunofluorescence Assay testing for H1N1 influenza is unreliable in ICU patients, according to a new study from Stanford University. Multiple methods exist for diagnosing influenza, but data on the utility and accuracy of these tests for H1N1 are still emerging, given the relatively recent onset of the epidemic.
In an article published online this week in Nature Genetics, a University of Colorado Cancer Center team in partnership with universities in China and Denmark reports the first genetic sequencing of urothelial (transitional) carcinoma, the most prevalent type of bladder cancer.
Black women have higher recurrence and mortality rates than non-Hispanic white women for certain types of breast cancer, according to a University of Illinois Chicago researcher's study published recently in JAMA Oncology.
Tecan is working with Miltenyi Biotec, a leading provider of cell biology solutions, to develop a range of automated solutions for cell biology, based on the powerful MACS(R) Magnetic bead technology. This new agreement will allow customers to benefit from the advanced capabilities of Tecan's Freedom EVO(R) liquid handling platforms when performing a wide range of separation, cultivation and analysis processes for cells and biomolecules.
Scientists from Virginia Commonwealth University Massey Cancer Center have provided evidence from preclinical experiments that a gene known as melanoma differentiation associated gene-9/syntenin (mda-9/syntenin) could be used as a therapeutic target to kill bladder cancer cells, help prevent metastasis and even be used to non-invasively diagnose the disease and monitor its progression.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kathi Theade, MD 1233 N 30th St, Billings, MT 59101-0127 Ph: (406) 237-4116 | Kathi Theade, MD 1233 N 30th St, Billings, MT 59101-0127 Ph: (406) 237-4116 |
News Archive
Direct Immunofluorescence Assay testing for H1N1 influenza is unreliable in ICU patients, according to a new study from Stanford University. Multiple methods exist for diagnosing influenza, but data on the utility and accuracy of these tests for H1N1 are still emerging, given the relatively recent onset of the epidemic.
In an article published online this week in Nature Genetics, a University of Colorado Cancer Center team in partnership with universities in China and Denmark reports the first genetic sequencing of urothelial (transitional) carcinoma, the most prevalent type of bladder cancer.
Black women have higher recurrence and mortality rates than non-Hispanic white women for certain types of breast cancer, according to a University of Illinois Chicago researcher's study published recently in JAMA Oncology.
Tecan is working with Miltenyi Biotec, a leading provider of cell biology solutions, to develop a range of automated solutions for cell biology, based on the powerful MACS(R) Magnetic bead technology. This new agreement will allow customers to benefit from the advanced capabilities of Tecan's Freedom EVO(R) liquid handling platforms when performing a wide range of separation, cultivation and analysis processes for cells and biomolecules.
Scientists from Virginia Commonwealth University Massey Cancer Center have provided evidence from preclinical experiments that a gene known as melanoma differentiation associated gene-9/syntenin (mda-9/syntenin) could be used as a therapeutic target to kill bladder cancer cells, help prevent metastasis and even be used to non-invasively diagnose the disease and monitor its progression.
› Verified 6 days ago
Dr. Mark David Schaefer, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1233 N 30th St, Billings, MT 59101 Phone: 406-237-4116 | |
Richard Lammers, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1233 N 30th St, Billings, MT 59101 Phone: 406-237-4116 Fax: 406-237-4125 | |
Deniz Tek, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1233 N 30th St, Billings, MT 59101 Phone: 406-237-4116 Fax: 406-237-4125 | |
Jedediah Owen Walker, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2800 10th Ave N, Billings, MT 59101 Phone: 406-238-2500 | |
James Evan Buchan, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1233 N 30th St, Billings, MT 59101 Phone: 406-237-4116 Fax: 406-237-4125 | |
Samuel Leon Paczkowski, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1233 N 30th St, Billings, MT 59101 Phone: 406-237-4116 Fax: 406-237-4125 | |
Douglas Parker, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1233 N 30th St, Billings, MT 59101 Phone: 406-237-4116 Fax: 406-237-4125 |